Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | LIPE | Q05469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4316698 | 0.80 | CTSL (0.33) | PKMSMN1; SMN2LIPE | |
| SCHEMBL5948848 | 0.79 | CACNA1B (0.36) | PKMSMN1; SMN2LIPE | |
| SCHEMBL4317287 | 0.76 | — | — | |
| SCHEMBL4318920 | 0.76 | — | — | |
| SCHEMBL7451819 | 0.71 | TAS1R3 (0.32) | — | |
| SCHEMBL6203392 | 0.71 | BTK (0.32) | — | |
| SCHEMBL4316839 | 0.70 | MEN1 (0.38) | PKMSMN1; SMN2LIPE | |
| SCHEMBL6273909 | 0.69 | TAS1R3 (0.32) | — | |
| SCHEMBL17152289 | 0.69 | OPRK1 (0.34) | SMN1; SMN2 | |
| SCHEMBL6391548 | 0.68 | KMT2A (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194787-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-08-31 | — | — | US | claimed |
| US-20040044201-A1 | Protease inhibitors | GLAXOSMITHKLINE LLC | 2004-03-04 | — | — | US | claimed |
| US-7071184-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194787-A1 | Protease inhibitors | CTSK, CTSL, CTSZ | PKM 911/4885SMN1; SMN2 4497/4885LIPE 1785/4885 |
| US-20040044201-A1 | Protease inhibitors | CTSK, CTSE, CTSZ | PKM 1175/4885SMN1; SMN2 4434/4885LIPE 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.